RESUMEN
The beneficial effects of green tea have been confirmed in various diseases, such as different types of cancer, heart disease, and liver disease. The effective components of green tea mainly include tea polysaccharides and tea polyphenols, such as catechin, particularly (-)-epigallocatechin-3-gallate. Increasing in vivo and in vitro evidences have explored the potential molecular mechanisms of green tea as well as the specific biological actions. Moreover, clinical trials have also explored the potential value of green tea components in treating metabolic syndromes, such as obesity, type II diabetes, and cardiovascular disease. This study explores the effects of the two major green tea components on the improvement of type II diabetes. It is concluded that regular consumption of green tea is beneficial for the improvement of high-fat dietary-induced obesity and type II diabetes.
Asunto(s)
Diabetes Mellitus Tipo 2/prevención & control , Té/química , Animales , Antioxidantes/química , Antioxidantes/aislamiento & purificación , Antioxidantes/uso terapéutico , Catequina/análogos & derivados , Catequina/química , Catequina/aislamiento & purificación , Catequina/uso terapéutico , Ensayos Clínicos como Asunto , Humanos , Hipoglucemiantes/química , Hipoglucemiantes/aislamiento & purificación , Hipoglucemiantes/uso terapéutico , Insulina/metabolismo , Polifenoles/química , Polifenoles/aislamiento & purificación , Polifenoles/uso terapéutico , Polisacáridos/química , Polisacáridos/aislamiento & purificación , Polisacáridos/uso terapéutico , Transducción de Señal , Té/metabolismoRESUMEN
Green tea is one of the most popular beverages around the world. For several decades, numerous epidemiological, preclinical and clinical studies have demonstrated that green tea polyphenols (GTPs), especially epigallocatechin-3-gallate (EGCG) have cancer-preventing effects on various cancers. In this review, we present inhibition of carcinogenesis in different animal models by GTPs or EGCG, including prostate cancer, bladder cancer, breast cancer, intestinal cancer, colon cancer, gastric cancer, lung cancer, oral cancer and skin cancer. In vitro studies showed that GTPs/EGCG potently induces apoptosis, cell cycle arrest and suppresses metastasis in tumor cells but not in their normal cell counterparts. The molecular mechanisms of these activities are discussed in detail to elucidate GTPs/EGCG downstream carcinogenesis signaling pathways and their values of perspective of chemoprevention and treatment for cancers.